In the last years , the main topoisomerase I inhibitors ( TP1-I ) ( i.e. topotecan and irinotecan ) have been used in combination chemotherapy in non-small cell lung cancer .
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.  In the last years , the main topoisomerase I inhibitors ( TP1-I ) ( i.e. topotecan and irinotecan ) have been used in combination chemotherapy in non-small cell lung cancer . Several drugs (also alternative to cisplatin) have been used in combination with TP1-I, but to date the higher remission rate obtained with combinations is not translated into a more prolonged survival in comparison with TP1-I given alone. On the other hand, the toxicity of TP1-I combinations is greater than those of TP1-I used alone. The superior efficacy of combinations versus TP1-I used alone remains an open question. Furthermore, the best schedule for TP1-I has not been completely elucidated. Randomised studies are few (only two phase III trials) and only controlled studies will be able to clarify the best TP1-I combination regimen.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.  In the last years , the main topoisomerase I inhibitors ( TP1-I ) ( i.e. topotecan and irinotecan ) have been used in combination chemotherapy in non-small cell lung cancer . Several drugs (also alternative to cisplatin) have been used in combination with TP1-I, but to date the higher remission rate obtained with combinations is not translated into a more prolonged survival in comparison with TP1-I given alone. On the other hand, the toxicity of TP1-I combinations is greater than those of TP1-I used alone. The superior efficacy of combinations versus TP1-I used alone remains an open question. Furthermore, the best schedule for TP1-I has not been completely elucidated. Randomised studies are few (only two phase III trials) and only controlled studies will be able to clarify the best TP1-I combination regimen.

            ### Response:
            topotecan, irinotecan
            